Note 9 - Notes Payable |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2019 | |||
Notes to Financial Statements | |||
Debt Disclosure [Text Block] |
Platinum-Montaur Life Sciences LLC In July 2012, we entered into an agreement with Platinum-Montaur to provide us with a credit facility of up to $50 million (the “Platinum Loan Agreement”). In March 2017, the Company repaid to PPCO an aggregate of approximately $7.7 million in partial satisfaction of the Company’s liabilities, obligations and indebtedness under the Platinum Loan Agreement between the Company and Platinum-Montaur, which were transferred by Platinum-Montaur to PPCO. In November 2018, the Company issued 925,000 shares of common stock of Navidea to Dr. Goldberg, of which approximately 817,857 shares valued at $3.2 million were applied as payment of the Platinum debt, including principal and accrued interest of $2.2 million and loss on extinguishment of debt of $1.0 million. See Note 11.
During the three -month period ended March 31, 2018,
$42,000 of interest was compounded and added to the balance of the Platinum Note.IPFS Corporation In November 2017, we prepaid $396,000 of insurance premiums through the issuance of a note payable to IPFS Corporation (“IPFS”) with an interest rate of 4.0%. The note was payable in ten monthly installments of $40,000, with the final payment made in August 2018. In November 2018, we prepaid $393,000 of insurance premiums through the issuance of a note payable to IPFS with an interest rate of 5.1%. The note is payable in ten monthly installments of $40,000, with the final payment due in August 2019.
Interest expense related to the IPFS notes payable totaled $4,000 and $2,000 during the three -month periods ended March 31, 2019 and 2018, respectively. The balance of the IPFS note was approximately $199,000 and $316,000 as of March 31, 2019 and December 31, 2018, respectively, and was included in notes payable, current in the consolidated balance sheets.Summary During the
three -month periods ended March
31, 2019 and 2018, we recorded interest expense of $4,000 and $44,000, respectively, related to our notes payable. Of these amounts, $0 and $42,000 was compounded and added to the balance of our notes payable during the three -month periods ended March
31, 2019 and 2018, respectively. |